Single-cell RNA Sequencing Identifies Prognostic Biomarkers in Extramedullary Multiple Myeloma.

IF 3.5 4区 医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY
Menghan Yang, Fan Yu, Hui Qin
{"title":"Single-cell RNA Sequencing Identifies Prognostic Biomarkers in Extramedullary Multiple Myeloma.","authors":"Menghan Yang, Fan Yu, Hui Qin","doi":"10.2174/0109298673352012250414100227","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Multiple myeloma (MM) is the second most common hematologic malignancy, accounting for approximately 10% of all hematological cases, with higher morbidity and mortality.</p><p><strong>Objective: </strong>This study aimed to investigate the clonal evolutionary characteristics to identify novel prognostic biomarkers associated with extramedullary progression in MM.</p><p><strong>Methods: </strong>We downloaded transcriptomic profiles and single-cell microarray (scRNA-seq) data from public databases. Then, we used the LASSO method to develop a prognostic signature and validated its efficacy using external MM cohorts. We evaluated the differences in the immune microenvironment and drug sensitivity (IC50) between the different risk score groups. scRNA-seq analysis identified key cell types through AUCell scores, cell communication, and differentiation trajectory analyses.</p><p><strong>Results: </strong>In total, 126 DEGs were identified as crucial genes associated with extramedullary and intramedullary MM. After LASSO analysis, seven signature genes were selected to develop a risk score model, and high-risk patients showed worse outcomes. Subsequently, the nomogram incorporating age, albumin, b2m, LDH, and RiskScore predicted 1-, 3-, and 5-year outcomes with high AUCs. Immune analyses showed that 25 immune cell types, 35 immune checkpoints, 27 chemokines, 20 MHC molecules, and 14 receptor- related genes differed significantly between the two risk groups. We also identified 116 drugs (roscovitine and JNK inhibitor VIII) with significantly different IC50 values between the two risk groups. CD4+ T cells exhibited the highest signature gene activity. CellChat analysis demonstrated enhanced communication between CD4+, NK, and CD8+ T cells.</p><p><strong>Conclusion: </strong>Our study has proposed a risk score model based on seven identified signature genes for MM prognosis and revealed CD4+ T cells to be a major immune cell type associated with MM progression, contributing to personalized treatment decision-making and precise risk stratification of MM.</p>","PeriodicalId":10984,"journal":{"name":"Current medicinal chemistry","volume":" ","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current medicinal chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0109298673352012250414100227","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Multiple myeloma (MM) is the second most common hematologic malignancy, accounting for approximately 10% of all hematological cases, with higher morbidity and mortality.

Objective: This study aimed to investigate the clonal evolutionary characteristics to identify novel prognostic biomarkers associated with extramedullary progression in MM.

Methods: We downloaded transcriptomic profiles and single-cell microarray (scRNA-seq) data from public databases. Then, we used the LASSO method to develop a prognostic signature and validated its efficacy using external MM cohorts. We evaluated the differences in the immune microenvironment and drug sensitivity (IC50) between the different risk score groups. scRNA-seq analysis identified key cell types through AUCell scores, cell communication, and differentiation trajectory analyses.

Results: In total, 126 DEGs were identified as crucial genes associated with extramedullary and intramedullary MM. After LASSO analysis, seven signature genes were selected to develop a risk score model, and high-risk patients showed worse outcomes. Subsequently, the nomogram incorporating age, albumin, b2m, LDH, and RiskScore predicted 1-, 3-, and 5-year outcomes with high AUCs. Immune analyses showed that 25 immune cell types, 35 immune checkpoints, 27 chemokines, 20 MHC molecules, and 14 receptor- related genes differed significantly between the two risk groups. We also identified 116 drugs (roscovitine and JNK inhibitor VIII) with significantly different IC50 values between the two risk groups. CD4+ T cells exhibited the highest signature gene activity. CellChat analysis demonstrated enhanced communication between CD4+, NK, and CD8+ T cells.

Conclusion: Our study has proposed a risk score model based on seven identified signature genes for MM prognosis and revealed CD4+ T cells to be a major immune cell type associated with MM progression, contributing to personalized treatment decision-making and precise risk stratification of MM.

单细胞RNA测序鉴定髓外多发性骨髓瘤的预后生物标志物。
背景:多发性骨髓瘤(MM)是第二常见的血液恶性肿瘤,约占所有血液病例的10%,具有较高的发病率和死亡率。目的:本研究旨在研究mm的克隆进化特征,以确定与髓外进展相关的新型预后生物标志物。方法:从公共数据库下载转录组图谱和单细胞微阵列(scRNA-seq)数据。然后,我们使用LASSO方法建立预后特征,并使用外部MM队列验证其有效性。我们评估了不同风险评分组之间免疫微环境和药物敏感性(IC50)的差异。scRNA-seq分析通过AUCell评分、细胞通讯和分化轨迹分析确定了关键细胞类型。结果:共有126个基因被鉴定为髓外和髓内MM相关的关键基因。LASSO分析后,选择7个特征基因建立风险评分模型,高危患者预后较差。随后,结合年龄、白蛋白、b2m、LDH和RiskScore的nomogram预测了高auc的1年、3年和5年预后。免疫分析显示,25种免疫细胞类型、35个免疫检查点、27种趋化因子、20种MHC分子和14种受体相关基因在两个风险组之间存在显著差异。我们还发现116种药物(罗斯科维汀和JNK抑制剂VIII)在两个风险组之间具有显著不同的IC50值。CD4+ T细胞表现出最高的特征基因活性。CellChat分析显示CD4+、NK和CD8+ T细胞之间的通讯增强。结论:本研究建立了一种基于已鉴定的7个MM预后特征基因的风险评分模型,揭示CD4+ T细胞是MM进展相关的主要免疫细胞类型,有助于MM的个性化治疗决策和精确的风险分层。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Current medicinal chemistry
Current medicinal chemistry 医学-生化与分子生物学
CiteScore
8.60
自引率
2.40%
发文量
468
审稿时长
3 months
期刊介绍: Aims & Scope Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews and guest edited thematic issues written by leaders in the field covering a range of the current topics in medicinal chemistry. The journal also publishes reviews on recent patents. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信